It is not uncommon to come across patients on platelet altering medications requiring a minor oral surgical procedure in clinical practice. Although, now it remains an evidence based common consensus among practicing maxillofacial and oral surgeons to not to stop platelet altering medication before a minor oral surgical procedure, many clinicians prefer to assess bleeding parameters before a surgical intervention. It is usually noticed that the laboratory investigation(s) ordered to assess haemostasis in patients on platelet altering medications are irrelevant or unnecessary. In cases where the treating clinician/dentist prefers to order a laboratory investigation, it should be targeted to serve the intended purpose. Stopping the low-dose aspirin 7-10 days before oral surgery procedures is still being practiced by some clinicians due to the mere fear of a bleed intra or post operatively, which renders the patient to an increased risk of a thromboembolic event. Similarly some clinicians prefer stopping other platelet altering medications too. Currently there is sufficient clinical evidence available to support non-stoppage of platelet altering medications for a minor oral surgical procedure in patients taking these drugs for various medical problems. The benefit of prevention of a thromboembolic episode in a patient outweighs the risk of minor bleeding, that if happens can be easily controlled by local measures. Ordering haematological investigation to assess haemostasis purely remains a treating clinician's personal preference and may be wise at some centers for legal purposes and prevention of litigations. The commonly prescribed platelet altering medications in clinical use are aspirin, clopidogrel and dipyridamole. Each of these medications has a well defined and specific mechanism of action to produce the desired pharmacological effect. (Table 1) [1] The best screening test recommended to assess the effect of platelet altering medications on cessation of bleeding may be evaluated with the platelet function analyser, which may not be available at all haematological laboratories. The Ivy bleeding time is the alternate test to assess and screen patients on platelet function altering medication. [2] It needs emphasis that investigations that assess coagulation cascade like prothrombin time (PT), partial thromboplastin time (PTT) or activated partial thromboplastin time (aPTT) and international normalized ratio (INR), have 'no' role in screening patients on medication that alter platelet function. Some authors do not recommend any laboratory monitoring for patients on aspirin therapy as bleeding time test is not a very reliable indicator of anticipating post-surgical haemorrhage in these patients [3] . 
